Skip to main content
SpringerLink
Log in

Cancer drug discovery: the wisdom of imprecision

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Drug discovery is either an exact business that is based on detailed knowledge of target structure or it is a fishing expedition that uncovers new drugs through screening of random compounds for their biological effect on target function. Isolation of a new p53 activator with anticancer properties strengthens the reputation of this second approach (pages 1321–1328).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Disrupting p53–HDM-2 interaction by small molecules: two targeting approaches.

References

  1. Issaeva, N. et al. Nat. Med. 10, 1321–1328 (2004).

    Article  CAS  Google Scholar 

  2. Fischer, P.M. & Lane, D.P. Trends Pharmacol. Sci. 25 343–346 (2004).

    Article  CAS  Google Scholar 

  3. Vassilev, L.T. et al. Science 303, 844–848 (2004).

    Article  CAS  Google Scholar 

  4. Bykov, V.J. et al. Nat. Med. 8, 282–288 (2002).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Genetics, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Andrei V Gudkov

Authors
  1. Andrei V Gudkov
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gudkov, A. Cancer drug discovery: the wisdom of imprecision. Nat Med 10, 1298–1299 (2004). https://doi.org/10.1038/nm1204-1298

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1204-1298

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation